Select Language
NY-ESO-1
NY-ESO-1 Overview
| English Name | Cancer/testis antigen 1 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 25 | Target Synonym | CTAG1A more，Autoimmunogenic cancer/testis antigen NY-ESO-1，LAGE2A，CTAG1，CTAG1A，CTAG1B，Cancer/Testis Antigen 1B，Cancer/Testis Antigen 6.1，L Antigen Family Member 2，Cancer/Testis Antigen 1，LAGE-2，LAGE2B，CT6.1，CTAG，ESO1，Cancer Antigen 3，NY-ESO-1，LAGE2，New York Esophageal Squamous Cell Carcinoma 1 |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Cancer/testis antigen 1 |
| Target Synonym | CTAG1A more，Autoimmunogenic cancer/testis antigen NY-ESO-1，LAGE2A，CTAG1，CTAG1A，CTAG1B，Cancer/Testis Antigen 1B，Cancer/Testis Antigen 6.1，L Antigen Family Member 2，Cancer/Testis Antigen 1，LAGE-2，LAGE2B，CT6.1，CTAG，ESO1，Cancer Antigen 3，NY-ESO-1，LAGE2，New York Esophageal Squamous Cell Carcinoma 1 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 25 |
| Highest Development Stage | Phase 3 Clinical |
NY-ESO-1 Product List
- Product Category
Cell (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
Tag Free (1)
- Conjugate
- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
CHEK-STP114 |  Human | HEK293 | NY-ESO-1 specific TCR-HEK293 cell line |  |
Total: 1
- 1
NY-ESO-1 Background
Cluster of Differentiation 3 (CD3) is a pivotal multimeric T cell co-receptor complex essential for adaptive immune responses. Composed of epsilon (ε), gamma (γ), delta (δ), and zeta (ζ) polypeptide chains forming three distinct dimers (εγ, εδ, ζζ), CD3 non-covalently associates with the T-cell receptor (TCR) to establish the critical TCR/CD3 receptor complex on T cell surfaces. Structurally, CD3 proteins belong to the immunoglobulin superfamily, featuring a transmembrane domain, an N-terminal extracellular region with immunoglobulin-like domains, and cytoplasmic tails embedded with immunoreceptor tyrosine-based activation motifs (ITAMs). These ITAMs are fundamental for initiating signal transduction upon T cell receptor engagement, thereby activating both CD4+ T helper and CD8+ cytotoxic T cells. As a defining marker of the T cell lineage, CD3's central role in T cell activation makes its modulation, via stimulating or blocking antibodies, a promising therapeutic avenue for conditions like organ transplant rejection and autoimmune diseases.
NY-ESO-1 Synonyms
NY-ESO-1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| mipetresgene autoleucel | TBI-1301 | Phase 3 Clinical | Takara Bio Inc | Esophageal Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Sarcoma, Synovial; Solid tumours; Urinary Bladder Neoplasms | Details |
| TCR Affinity Enhancing Specific T cell Therapy | TAEST-16001 | Phase 2 Clinical | Guangzhou Institute Of Respiratory Health, Guangzhou Xiangxue Pharmaceutical Co Ltd | Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Osteosarcoma; Ovarian Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms | Details |
| Cancer vaccine NY-ESO-1 (Ludwig Institute/Peking University/Jewim Pharmaceutical) | Phase 2 Clinical | Ludwig Institute For Cancer Research | Liver Neoplasms; Melanoma | Details | |
| Anti-NY-ESO-1 TCR-T cell theray (Shenzhen BinDeBio) | Phase 2 Clinical | Shenzhen Bindebio Ltd | Carcinoma, Hepatocellular; Esophageal Neoplasms; Glioma; Stomach Neoplasms | Details | |
| Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes (Roswell) | CD8-TCR-T cells; NY-ESO-1/CD8/HL AA2.1-19305dp-TCR-T cells | Phase 2 Clinical | Roswell Park Cancer Institute | Neoplasms | Details |
| VTP-600 | VTP-600 | Phase 2 Clinical | Barinthus Biotherapeutics PLC, Ludwig Institute For Cancer Research | Carcinoma, Non-Small-Cell Lung | Details |
| NY-ESO-1TCR/dnTGFBRII Engineered T Cells therapy (The University Of Chicago) | NY-ESO-1 TCR/ dnTGFβRII | Phase 2 Clinical | The University Of Chicago | Ovarian Neoplasms; Solid tumours | Details |
| NY-ESO-1 TCR/IL-15 NK | Phase 2 Clinical | Replay Holdings LLC, Syena, The University Of Texas MD Anderson Cancer Center | Liposarcoma, Myxoid; Multiple Myeloma; Sarcoma, Synovial | Details | |
| TC-N201(TCRCure) | TC-N201 | Phase 2 Clinical | Tcrcure Biopharma Ltd | Neoplasms; Solid tumours | Details |
| HBI-0201-ESO TCRT | HBI-0201-ESO TCRT | Phase 2 Clinical | Hadassah Medical Organization | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Sarcoma; Sarcoma, Synovial; Triple Negative Breast Neoplasms | Details |
| NY-ESO-1 TCR(Kite Pharma) | Phase 2 Clinical | Kite Pharma, National Cancer Institute | Esophageal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Meningioma; Neoplasm Metastasis; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details | |
| Letetresgene autoleucel | GSK-3377794; GSK-794 | Phase 2 Clinical | Adaptimmune Llc | Carcinoma, Non-Small-Cell Lung; Melanoma; Multiple Myeloma; Neoplasms; Ovarian Neoplasms | Details |
| Anti-NY-ESO-1 murine TCR transduced autologous peripheral blood lymphocytes (Albert Einstein College of Medicine/NCI) | Phase 1 Clinical | Albert Einstein College Of Medicine Inc, National Cancer Institute | Neoplasms | Details | |
| Neldaleucel | MT601; MT-601 | Phase 1 Clinical | Marker Therapeutics Inc | Hodgkin Disease; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | Details |
| Super 1 T-cell receptor therapy (Guangzhou FineImmune Biotechnology) | Phase 1 Clinical | Guangzhou Fineimmune Biotechnology | Lung Neoplasms; Melanoma; Sarcoma; Solid tumours | Details | |
| PeptiCRAd-1 | Valo-D102; PeptiCRAd-1 | Phase 1 Clinical | Valor Biotherapeutics | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liposarcoma, Myxoid; Neoplasms; Osteosarcoma; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Triple Negative Breast Neoplasms | Details |
| Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 (LauT-1) therapy(Centre Hospitalier Universitaire Vaudois) | LauT-1 | Phase 1 Clinical | Centre Hospitalier Universitaire Vaudois | Melanoma; Sarcoma | Details |
| DS-2243 | DS-2243a; DS-2243 | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Sarcoma; Solid tumours | Details |
| SY-104 | SY-104 | Phase 1 Clinical | Replay Holdings LLC | Multiple Myeloma; Sarcoma | Details |
| MDG-1015 | MDG1015; MDG-1015 | Phase 1 Clinical | Medigene Ag | Carcinoma, Ovarian Epithelial; Gastroesophageal Junction Neoplasms; Liposarcoma; Liposarcoma, Myxoid; Ovarian Neoplasms; Sarcoma, Synovial; Soft Tissue Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| TCR-T cells（Fujian Province Tumor Hospita） | Phase 1 Clinical | Fujian Cancer Hospital | Solid tumours | Details | |
| LYL-132 | LYL-132; GSK-4427296 | Phase 1 Clinical | Lyell Immunopharma Inc | Neoplasms; Solid tumours | Details |
| HLA-A*02:01/NY-ESO-1 TCR-T cell therapy (Pregene) | Phase 1 Clinical | Shenzhen Pregene Biopharma Co Ltd | Sarcoma | Details | |
| anti-NY-ESO-1 TCR T-cell therapy (Shenzhen BinDeBio) | Clinical | Shenzhen Bindebio Ltd | Neoplasms | Details | |
| NYESOiNT | Clinical | Eutilex | Neoplasms; Ovarian Neoplasms; Sarcoma | Details |
- Overview
- Product List
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland